Ubrogepant: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Ubrogepant. Educational only — not medical advice.
Labeled uses
UBRELVY is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine.
Source: FDA labeling via NIH DailyMed (set fd9f9458…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.